On September 16, 2026, Meiryu Hospital in Japan officially issued a license certificate (Number: NO.2026-007), granting permission to Leduo Technology (Beijing) Co., Ltd. (Brand Name: Lerawa International Fertility Assistance) to cooperate in various areas such as online and offline health education, reproductive medical consultation, patient scheduling, hospital logistics support, and marketing promotion. This authorization signifies a further improvement in Lerawa International Fertility Assistance's medical service offerings abroad.

I. Cooperation License

The key information from the license issued by Meiryu Hospital in Japan is as follows:

Meiryu Hospital License No. 2026-007

The authorization document also states that this document is the sole valid text and must not be copied, altered, or transferred to third parties without the authorization of the issuing authority. This written document provides a direct basis for customers to understand and verify the relationship between both parties.

II. JapanMizuho HospitalIntroduction

Mizuho HospitalFounded in Tokyo, Japan, Mizuho Hospital is a medical institution specializing in assisted reproduction and regenerative medicine. It has a headquarters in Akasaka and a branch in Shinjuku. The hospital brings together global resources in the field of assisted reproduction, providing one-stop services for individuals and families who need cross-border reproductive medical care.

●Hospital layout: The Akasaka headquarters features a luxurious and high-quality space with a thousand-level sterile embryo laboratory, equipped with time-lapse culture systems and high-precision gene sequencing instruments. The Shinjuku branch has soft lighting, a user-friendly layout, and strong privacy features, featuring high-standard operating platforms and various functional rooms.

●Assisted reproductive services: Include third-generation in vitro fertilization (PGT-A/PGT-M/PGT-SR), intracytoplasmic sperm injection (ICSI), embryo cultivation and transplantation, frozen eggs, sperm, and embryos, as well as fertility preservation and treatment for infertility.

● Reproductive medical services: Includes ovarian stem cell therapy, endometrial regeneration and repair, egg quality optimization, exosomes and PRP for ovarian function improvement, ovarian tissue freezing and autologous transplantation for regeneration.

● Treatment plans: Follows Japanese standards for embryo cultivation quality control. Mild stimulation protocols are commonly used. Reproductive physicians customize treatment plans based on individual ovarian and endocrine conditions, ensuring both precision medicine and overall health maintenance.

● Medical team: A bilingual medical team consisting of Director Hidetaka Hoshiguchi, Deputy Director Keiaki Suzuki, Dr. Chiyo Chida, and Dr. Mitsuo Terada has been established.

It should be noted that all diagnostic and treatment procedures mentioned above are carried out at Mizuho Hospital in Japan. Service details are subject to the official hospital information and any agreed terms between the parties.

III. Leilawa International Fertility Assistance: Further Expansion in Japan

Leilawa International Fertility Assistance is a brand under Leidom Technology (Beijing) Co., Ltd. It provides domestic consulting services for clients who need information about fertility abroad. Services include consultation and planning for in vitro fertilization, fertility preservation, customized reproductive solutions, genetic testing of embryos (PGT), as well as medical translation, travel and accommodation arrangements, accompaniment during medical treatments abroad, and follow-up after returning home.

This authorization from Mizuho Hospital in Japan is another step forward for Leilawa in its international medical cooperation network. After collaborating with INCINTA Hospital in the United States, Alfa in Malaysia, and IRMC in Kyrgyzstan, this collaboration with Mizuho Hospital in Japan further expands Leilawa's global reach.

● The cooperation relationship is verifiable: Both parties rely on an official authorization certificate (NO.2026-007) as a written basis for their cooperation. The duration and scope of the services are clearly specified, allowing customers to obtain accurate information through official channels.

● Transparent information access: Information about Mizuha Hospital's locations, service items, and procedures can be obtained through domestic consultation channels.

● smoother medical treatment processes: With authorized services in place, customers' travel arrangements to Japan and hospital reception processes become more organized.

● Use only official documents: The authorization letter must be the original document. Customers should be careful to distinguish between photocopies and sub-authorized documents when verifying the cooperation relationship.

V. Future Prospects for Cooperation

During the authorized period, both parties will continue to improve the consultation mechanisms for customers in China, focusing on health education, reproductive medical consultations, patient scheduling, and other related services. Leilawa International Assistance for Pregnancy will also continue to expand its cooperation with more overseas medical institutions, gradually expanding its service network globally.

1. What is the relationship between LeLaiWa International Fertility Assistance and Meiryue Hospital in Japan?

The two parties have established an authorized partnership. The authorization certificate issued on September 16, 2026 (No. 2026-007) confirms that Meiryue Hospital has authorized LeDomi Technology (Beijing) Co., Ltd. (brand name: LeLaiWa International Fertility Assistance) to carry out cooperation in various areas such as online and offline health education, reproductive medical consultation, patient scheduling, hospital logistics support, and marketing promotion. This authorization lasts until September 15, 2027.

Meiryue Hospital was founded in Tokyo, Japan. Its services include third-generation embryo transfer (PGT), egg freezing for fertility preservation, infertility treatment, as well as regenerative medical treatments such as ovarian stem cell therapy and endometrial regeneration. For detailed service offerings, please refer to the official hospital information.

Customers who require such services can contact LeLaiWa's official website (www.lelaiwa.com) or through customer service at 18101365219. An internal consulting team will assess and coordinate the process. Diagnosis and treatment will be carried out by Meiryue Hospital and its licensed physicians. Specific service details shall be subject to mutual agreement between the two parties.

This authorization represents another step towards standardized cooperation between LeLaiWa International Fertility Assistance and overseas medical institutions. It also provides families interested in reproductive medical information in Japan with a written basis for consultation. If you wish to learn more about Meiryue Hospital or seek cross-border reproductive medical services, please visit LeLaiWa's official website.

www.lelaiwa.com or contact the official customer service at 18101365219.

Note: The information in this article is based on the authorization certificate issued by Meishu Hospital in Japan (No. 2026-007) and public information provided by the hospital. Service offerings are subject to mutual agreements and the latest information from the hospital. Cross-border medical treatment must comply with Chinese laws and regulations, as well as Japanese relevant rules. All diagnoses and treatments are conducted by qualified medical institutions and licensed physicians. Le Laiwa International Assistance in Childbirth provides consulting and supportive services only; it does not warrant any medical outcomes.